Eli Lilly and Company - Product Pipeline Review - 2015

Published: Apr, 2015 | Pages: 251 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Eli Lilly and Company - Product Pipeline Review - 2015

Summary 

Global Markets Direct's, 'Eli Lilly and Company - Product Pipeline Review - 2015', provides an overview of the Eli Lilly and Company's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Eli Lilly and Company's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Eli Lilly and Company including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Eli Lilly and Company's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Eli Lilly and Company's pipeline products

Reason To Buy 

- Evaluate Eli Lilly and Company's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Eli Lilly and Company in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Eli Lilly and Company's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Eli Lilly and Company and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Eli Lilly and Company
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Eli Lilly and Company and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 7
Eli Lilly and Company Snapshot 8
Eli Lilly and Company Overview 8
Key Information 8
Key Facts 8
Eli Lilly and Company - Research and Development Overview 9
Key Therapeutic Areas 9
Eli Lilly and Company - Pipeline Review 18
Pipeline Products by Stage of Development 18
Pipeline Products - Monotherapy 19
Pipeline Products - Combination Treatment Modalities 20
Pipeline Products - Partnered Products 21
Pipeline Products - Out-Licensed Products 24
Eli Lilly and Company - Pipeline Products Glance 26
Eli Lilly and Company - Late Stage Pipeline Products 26
Eli Lilly and Company - Clinical Stage Pipeline Products 29
Eli Lilly and Company - Early Stage Pipeline Products 34
Eli Lilly and Company - Unknown Stage Pipeline Products 36
Eli Lilly and Company - Drug Profiles 37
dulaglutide 37
duloxetine hydrochloride DR 40
necitumumab 42
ramucirumab 45
cetuximab 50
abemaciclib 57
baricitinib 58
evacetrapib 61
insulin peglispro 63
ixekizumab 65
LY-2951742 66
odelepran hydrochloride 67
solanezumab 68
tadalafil 70
edivoxetine 72
galunisertib 74
blosozumab 76
emibetuzumab 77
erteberel 78
insulin lispro U100 79
LY-2409021 81
LY-2495655 82
LY-2510924 83
LY-2606368 84
LY-2623091 85
LY-2928057 86
LY-2940094 87
LY-2944876 88
LY-3015014 90
LY-3016859 91
LY-3023414 92
merestinib 94
olaratumab 95
pemetrexed disodium 97
ralimetinib mesylate 103
taladegib 104
Biologic 3 for Diabetes 105
Biologic 4 for Diabetes 106
Biologic 5 for Diabetes 107
Biologic for Anemia 108
Biologic for Crohn's Disease 109
Biologic for Diabetic Nephropathy 110
Biologic for Hypoglycemia 111
Biologic for Lupus 112
Biologic for Ulcerative Colitis 113
LY-2608204 114
LY-2780301 115
LY-2874455 116
LY-2922083 117
LY-2922470 118
LY-2969822 119
LY-2979165 120
LY-3002813 121
LY-3009120 122
LY-3022855 123
LY-3022856 124
LY-3025876 125
LY-3039478 126
LY-3041658 127
LY-3045697 128
LY-3050258 129
LY-3074828 130
LY-3079514 131
LY-3084077 132
LY-3090106 133
LY-3108743 134
LY-3113593 135
LY-3114062 136
LY-3127760 137
LY-3143753 138
LY-3154207 139
LY-3164530 140
LY-3185643 141
LY-3202626 142
LY-900014 143
Small Molecule for Hypertension 144
Small Molecule for Muscle Atrophy 145
Small Molecule to Agonize mGlu2/3 for Chronic Pain 146
cercosporamide 147
CPZEN-45 149
insulin lispro U200 150
insulin lispro U300 151
LLY-2707 152
LSN-2463359 153
LSN-2535717 154
LSN-2814617 155
LY-2109761 156
LY-2607540 157
LY-2857785 158
LY-3002813 + LY-2811376 159
Monoclonal Antibody Conjugate 1 for Cancer 160
Monoclonal Antibody Conjugate 2 for Cancer 161
Monoclonal Antibody Conjugate 3 for Cancer 162
ND-09759 163
Peptide for Type 2 Diabetes and Obesity 164
Small Molecule to Agonize TR-Beta for Dyslipidemia 165
Small Molecule to Antagonize mGlu5 for Pain 166
Monoclonal Antibodies for Cancer 167
Monoclonal Antibodies for Undisclosed Indication 168
Monoclonal Antibody Conjugates for Cancer 169
Small Molecule for Type 2 Diabetes 170
Small Molecules to Inhibit Beta Secretase for Alzheimer's Disease 171
LY-3000328 172
Eli Lilly and Company - Pipeline Analysis 173
Eli Lilly and Company - Pipeline Products by Target 173
Eli Lilly and Company - Pipeline Products by Route of Administration 179
Eli Lilly and Company - Pipeline Products by Molecule Type 180
Eli Lilly and Company - Pipeline Products by Mechanism of Action 181
Eli Lilly and Company - Recent Pipeline Updates 187
Eli Lilly and Company - Dormant Projects 214
Eli Lilly and Company - Discontinued Pipeline Products 218
Discontinued Pipeline Product Profiles 220
Eli Lilly and Company - Company Statement 229
Eli Lilly and Company - Locations And Subsidiaries 233
Head Office 233
Other Locations & Subsidiaries 233
Eli Lilly and Company - Key Manufacturing Facilities 241
Appendix 242
Methodology 242
Coverage 242
Secondary Research 242
Primary Research 242
Expert Panel Validation 242
Contact Us 242
Disclaimer 243

List of Tables

Eli Lilly and Company, Key Information 16
Eli Lilly and Company, Key Facts 16
Eli Lilly and Company - Pipeline by Indication, 2015 19
Eli Lilly and Company - Pipeline by Stage of Development, 2015 26
Eli Lilly and Company - Monotherapy Products in Pipeline, 2015 27
Eli Lilly and Company - Combination Treatment Modalities in Pipeline, 2015 28
Eli Lilly and Company - Partnered Products in Pipeline, 2015 29
Eli Lilly and Company - Partnered Products/ Combination Treatment Modalities, 2015 30
Eli Lilly and Company - Out-Licensed Products in Pipeline, 2015 32
Eli Lilly and Company - Out-Licensed Products/ Combination Treatment Modalities, 2015 33
Eli Lilly and Company - Pre-Registration, 2015 34
Eli Lilly and Company - Filing rejected/Withdrawn, 2015 35
Eli Lilly and Company - Phase III, 2015 36
Eli Lilly and Company - Phase II, 2015 37
Eli Lilly and Company - Phase I, 2015 39
Eli Lilly and Company - Preclinical, 2015 42
Eli Lilly and Company - Discovery, 2015 43
Eli Lilly and Company - Unknown, 2015 44
Eli Lilly and Company - Pipeline by Target, 2015 182
Eli Lilly and Company - Pipeline by Route of Administration, 2015 187
Eli Lilly and Company - Pipeline by Molecule Type, 2015 188
Eli Lilly and Company - Pipeline Products by Mechanism of Action, 2015 189
Eli Lilly and Company - Recent Pipeline Updates, 2015 195
Eli Lilly and Company - Dormant Developmental Projects,2015 222
Eli Lilly and Company - Discontinued Pipeline Products, 2015 226
Eli Lilly and Company, Subsidiaries 241
Eli Lilly and Company, Key Manufacturing Facilities 249